How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance.
Zenz
T
T
Häbe
S
S
Denzel
T
T
Winkler
D
D
Döhner
H
H
Stilgenbauer
S
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D017809:Fatal Outcome; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D000069283:Rituximab